IOVANCE BIOTHERAPEUTICS, INC. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
Iovance provided Q2 2026 revenue guidance of $86M–$88M and full-year 2026 guidance of $350M–$370M, representing ~45% year-over-year growth in Q1 2026. The company reported 90 authorized treatment centers (ATCs) as of May 7, 2026, ~1,500 patients treated with commercial and clinical TIL products, a cash position of $319M as of March 31, 2026, and a 41% gross margin in Q1 2026 impacted by one-time costs. The filing is a corporate overview presentation dated June 2026 covering Amtagvi (lifileucel) commercial performance and pipeline developments.
Why this rating
Revenue guidance reflects strong early commercial traction (~45% YoY growth) in a commercial-stage biotech, but company scale (~$535M market cap) makes even $350–370M annual revenue material. No material M&A, financing, or operational crises disclosed. Routine quarterly update with positive trajectory but not transformational.
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.